Sistemsko zdravljenje napredovalega diferenciranega raka ščitnice

Abstract

Diferencirani rak ščitnice predstavlja preko 90 odstotkov raka ščitnice. Nastane iz folikularnih celic ščitnice in spada med visoko ozdravljive rake. Primarno zdravljenje je kirurško, visoko rizični za ponovitev prejmejo še adjuvantno radiojodno terapijo in tiroksin v supresijskem odmerku. Pri 7-23% bolnikov pride do pojava zasevkov v oddaljenih organih (pljuča, skelet). Temelj zdravljenja metastatskega diferenciranega raka ščitnice je radiojodna terapija. Pri pojavu rezistence na radiojodno terapijo je ob napredovanju bolezni sedaj na voljo zdravljenje s tarčnim zdravilom sorafenibom.

Keywords

rak ščitnice;napredovali rak;zdravljenje;preživetje;

Data

Language:	Slovenian
Year of publishing:	2014
Typology:	1.02 - Review Article
Organization:	OI - Institute of Oncology
UDC:	616.4-006
COBISS:	1963131
ISSN:	1408-1741
Parent publication:	Onkologija
Views:	2241
Downloads:	557
Average score:	0 (0 votes)
Metadata:

Other data

Secondary language:	English
Secondary title:	Systemic treatment of advanced differentiated thyroid cancer
Secondary abstract:	Differentiated thyroid cancer represents over 90 percents of thyroid cancers. It arises from thyroid follicular cells and is one of highly treatable cancers. Primary treatment is surgical and patients at high risk of carcinoma recurrence also receive adjuvant radioiodine therapy and a suppressive dose of thyroxin. In 7–23% of patients metastases appear in remote organs (lungs, skeleton). The basic treatment for metastatic differentiated thyroid cancer is radioiodine therapy. In case of resistance to radioiodine therapy during disease progression, treatment is now also possible with target medication sorafenib.
URN:	URN:NBN:SI
Pages:	str. 89-91, 118
Volume:	ǂLetn. ǂ18
Issue:	ǂšt. ǂ2
Chronology:	dec. 2014
ID:	10957641